Arcturus Therapeutics Holdings Inc.
A San Diego-based company that makes messenger RNA (mRNA) medicines and vaccines, including a COVID-19 vaccine and experimental treatments for rare diseases. Founded in 2013 by two scientists, it is named after Arcturus, the brightest star in the constellation Boötes, whose Greek name means "Guardian of the Bear." Its delivery platform, called LUNAR, is designed to carry RNA molecules safely into human cells.
Bought 11.0K
Granted 600.0K · Sold 1.60M
Sold 297.2K
Granted 2.3K · Bought 31.9K · Sold 50.0K
Granted 3.1K · Bought 9.1K
Granted 3.1K · Bought 4.5K
Granted 3.1K
Granted 13.9K · Bought 950 · Sold 13.9K
Granted 3.1K
Granted 3.1K
Granted 3.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Payne Joseph EPresident and CEO, Director · 3 transactions | — | 1.48Mas of Nov 2022 | — | 11.0K | — |
| Ultragenyx Pharmaceutical Inc.Director · 5 transactions | — | 1.40Mas of Aug 2021 | 600.0K | — | 1.60M |
| Chivukula PadChief Scientific Officer & COO · 32 transactions | — | 435.3Kas of Oct 2024 | — | — | 297.2K |
| Sassine AndyChief Financial Officer, Director · 8 transactions | — | 221.8Kas of Aug 2025 | 2.3K | 31.9K | 50.0K |
| Farrell Peter CDirector · 3 transactions | — | 98.7Kas of Jun 2024 | 3.1K | 9.1K | — |
| Marquet MagdaDirector · 3 transactions | — | 28.1Kas of Jun 2024 | 3.1K | 4.5K | — |
| Barlow James FDirector · 1 transaction | — | 13.1Kas of Jun 2024 | 3.1K | — | — |
| Kummerfeld Keith CSee Remarks · 10 transactions | — | 6.9Kas of Jul 2023 | 13.9K | 950 | 13.9K |
| Holmes Edward WDirector · 1 transaction | — | 3.1Kas of Jun 2024 | 3.1K | — | — |
| Marantz Jing L.Director · 1 transaction | — | 3.1Kas of Jun 2024 | 3.1K | — | — |
| Markels JohnDirector · 1 transaction | — | 3.1Kas of Jun 2024 | 3.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -1.90M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.